Balance Sheet
Cash Flow Statement
Beginning Cash BalanceChange in Account PayablesCurrent DebtGains from Sales and DivestituresNet Debt Issuances and RepaymentsNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Change in Account Payables: 2018-2025

Historic Change in Account Payables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Sep 2025 value amounting to -$1.2 million.

  • China SXT Pharmaceuticals' Change in Account Payables rose 11.76% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71,329, marking a year-over-year decrease of 355.56%. This contributed to the annual value of -$114,081 for FY2025, which is 289.97% down from last year.
  • China SXT Pharmaceuticals' Change in Account Payables amounted to -$1.2 million in Q3 2025, which was down 201.54% from $1.2 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Change in Account Payables high stood at $1.5 million for Q1 2022, and its period low was -$1.5 million during Q3 2021.
  • For the 3-year period, China SXT Pharmaceuticals' Change in Account Payables averaged around $1,670, with its median value being -$8,946 (2025).
  • Within the past 5 years, the most significant YoY rise in China SXT Pharmaceuticals' Change in Account Payables was 26.11% (2021), while the steepest drop was 24.97% (2021).
  • Over the past 5 years, China SXT Pharmaceuticals' Change in Account Payables (MRQ) stood at -$1.5 million in 2021, then grew by 11.73% to -$1.3 million in 2022, then grew by 0.82% to -$1.3 million in 2023, then fell by 2.81% to -$1.3 million in 2024, then grew by 11.76% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, $1.2 million for Q1 2025, and -$1.3 million during Q3 2024.